Stay updated with breaking news from பதவி எக்ஸ்பிரஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pharmadrug Inc.: PharmaDrug Files For FDA Orphan Drug Designation For DMT In Kidney Transplantation and Expands on Its Psychedelics Strategy PharmaDrug or the Company ), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce it has expanded its psychedelic pharmaceutical program with the filing of an application with the U.S. Food and Drug Administration ( FDA ) to receive Orphan Drug Designation ( ODD ) for N,N-Dimethyltryptamine ( DMT ) in the prevention of ischemia reperfusion injury in patients undergoing kidney transplantation. Pharmaceutical Psychedelics Strategy Following the acquisition of Sairiyo Therapeutics and its biotech R&D core competencies, PharmaDrug has undertaken efforts to expand its research activities in the pharmaceutical psychedelics space. The Company s psychedel ....
The label came at a time when Trump’s presidential campaign was increasingly focused on protests and riots in liberal cities like Seattle, Portland and New York. ....
Nielsen water-treatment plant made eligible for $20 million loan for improvements journalnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from journalnow.com Daily Mail and Mail on Sunday newspapers.
Novel cartilage regenerative product, Chondro3 is a biomimetic graft for osteochondral lesions The Company's second FDA Breakthrough Device designation granted in 2021 Locate Bio, an orthobiologics ....
European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis NR2E3), for the treatment of both retinitis pigmentosa (RP) and Leber Congenital amaurosis (LCA). The prevalence of RP in Europe is estimated at approximately 165,000 patients and the prevalence of LCA in Europe is estimated at approximately 40,000 patients. Globally, the number of people suffering from RP and LCA is estimated to be around 2.0 million and 0.2 million, respectively. We believe the granting of this designation by the European Commission validates the potential of our modifier gene therapy platform to treat many inherited retinal diseases, Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen. ....